{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:52:19Z","timestamp":1791251539236,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"DOI":"10.1007\/s00467-026-07548-4","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:57:59Z","timestamp":1791190679000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["STEC-triggered DEAP-HUS in a toddler: successful management with eculizumab and mycophenolate mofetil without corticosteroids"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0528-9517","authenticated-orcid":false,"given":"Valentine","family":"Villada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Moussler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Vrillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Wiedemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"7548_CR1","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.pcl.2022.07.006","volume":"69","author":"O Boyer","year":"2022","unstructured":"Boyer O, Niaudet P (2022) Hemolytic-uremic syndrome in children. Pediatr Clin North Am 69:1181\u20131197. https:\/\/doi.org\/10.1016\/j.pcl.2022.07.006","journal-title":"Pediatr Clin North Am"},{"key":"7548_CR2","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.3390\/jcm13216499","volume":"13","author":"I Zago\u017cd\u017con","year":"2024","unstructured":"Zago\u017cd\u017con I, Szczepa\u0144ska M, Leszczy\u0144ska B et al (2024) Changing epidemiology and outcomes of hemolytic uremic syndrome in children: a prospective national cohort study from the Polish Pediatric HUS Registry and the Polish Registry of kidney Replacement Therapy in Children. J Clin Med 13:6499. https:\/\/doi.org\/10.3390\/jcm13216499","journal-title":"J Clin Med"},{"key":"7548_CR3","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra0902814","volume":"361","author":"M Noris","year":"2009","unstructured":"Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361:1676\u20131687. https:\/\/doi.org\/10.1056\/NEJMra0902814","journal-title":"N Engl J Med"},{"key":"7548_CR4","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00467-010-1446-9","volume":"25","author":"PF Zipfel","year":"2010","unstructured":"Zipfel PF, Mache C, M\u00fcller D et al (2010) DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome. Pediatr Nephrol 25:2009\u20132019. https:\/\/doi.org\/10.1007\/s00467-010-1446-9","journal-title":"Pediatr Nephrol"},{"key":"7548_CR5","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1182\/blood-2009-05-223834","volume":"114","author":"C Abarrategui-Garrido","year":"2009","unstructured":"Abarrategui-Garrido C, Mart\u00ednez-Barricarte R, L\u00f3pez-Trascasa M, de C\u00f3rdoba SR, S\u00e1nchez-Corral P (2009) Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 114:4261\u20134271. https:\/\/doi.org\/10.1182\/blood-2009-05-223834","journal-title":"Blood"},{"key":"7548_CR6","doi-asserted-by":"publisher","unstructured":"Holmes LV, Strain L, Staniforth SJ et al (2013) Determining the population frequency of the CFHR3\/CFHR1 deletion at 1q32. PLoS One 8:e60352. https:\/\/doi.org\/10.1371\/journal.pone.0060352","DOI":"10.1371\/journal.pone.0060352"},{"key":"7548_CR7","doi-asserted-by":"publisher","unstructured":"Mortari G, Bigatti C, Gaffi GP et al (2025) Shiga toxin-producing Escherichia coli infection as a precipitating factor for atypical hemolytic-uremic syndrome. Pediatr Nephrol 40:449\u2013461. https:\/\/doi.org\/10.1007\/s00467-024-06480-9","DOI":"10.1007\/s00467-024-06480-9"},{"key":"7548_CR8","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/ki.2013.373","volume":"85","author":"A Sinha","year":"2024","unstructured":"Sinha A, Gulati A, Saini S et al (2024) Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 85:1151\u20131160. https:\/\/doi.org\/10.1038\/ki.2013.373","journal-title":"Kidney Int"},{"key":"7548_CR9","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1007\/s00467-024-06373-x","volume":"39","author":"M Ferri","year":"2024","unstructured":"Ferri M, Zotta F, Donadelli R et al (2024) Anti-CFH-associated hemolytic uremic syndrome: do we still need plasma exchange? Pediatr Nephrol 39:3263\u20133269. https:\/\/doi.org\/10.1007\/s00467-024-06373-x","journal-title":"Pediatr Nephrol"},{"key":"7548_CR10","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00467-024-06530-2","volume":"40","author":"PA Coccia","year":"2025","unstructured":"Coccia PA, Alconcher LF, Ferraris V et al (2025) Eculizumab as first-line treatment for patients with severe presentation of complement factor H antibody-mediated hemolytic uremic syndrome. Pediatr Nephrol 40:1041\u20131047. https:\/\/doi.org\/10.1007\/s00467-024-06530-2","journal-title":"Pediatr Nephrol"},{"key":"7548_CR11","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00467-017-3612-9","volume":"32","author":"A Hackl","year":"2017","unstructured":"Hackl A, Ehren R, Kirschfink M et al (2017) Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS. Pediatr Nephrol 32:1081\u20131087. https:\/\/doi.org\/10.1007\/s00467-017-3612-9","journal-title":"Pediatr Nephrol"},{"key":"7548_CR12","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s00467-021-05025-8","volume":"36","author":"L Matrat","year":"2021","unstructured":"Matrat L, Bacchetta J, Ranchin B, Tann\u00e9 C, Sellier-Leclerc AL (2021) Pediatric atypical hemolytic-uremic syndrome due to auto-antibodies against factor H: is there an interest to combine eculizumab and mycophenolate mofetil? Pediatr Nephrol 36:1647\u20131650. https:\/\/doi.org\/10.1007\/s00467-021-05025-8","journal-title":"Pediatr Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07548-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07548-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07548-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:06:21Z","timestamp":1791248781000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-026-07548-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":12,"alternative-id":["7548"],"URL":"https:\/\/doi.org\/10.1007\/s00467-026-07548-4","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Oral informed consent was obtained from the patient\u2019s parents prior to publication of this case report. This retrospective description of the clinical case was approved by the local ethical committee (SAISINE 590).","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}